Combination therapy for b cell disorders
AssigneeGenentech, Inc.
InventorsAndrew Chan, Qian Gong, Flavius Martin
Life of this patent
Estimating the term…
Abstract
The invention provides methods of treating B cell based malignancies and B-cell regulated autoimmune disorders using a combination therapy of anti-CD20 antibody with a BLyS antagonist.
Claims53
A method of depleting B cells from a mixed population of cells comprising contacting the mixed population of cells with a BLyS antagonist and a CD20 binding antibody, wherein the BLyS antagonist is selected from the group consisting of a BR3 immunoadhesin, an anti-BLyS antibody, an anti-BR3 antibody, and a polypeptide having the sequence of SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, and SEQ ID NO. 10.
(canceled)
(canceled)
(canceled)
A method of treating a B cell neoplasm or malignancy characterized by B cells expressing CD20, comprising administering to a patient suffering from the neoplasm or malignancy, a therapeutically effective amount of a CD20 binding antibody and of a BLyS antagonist, wherein the BLyS antagonist is selected from the group consisting of a BR3 immunoadhesin, an anti-BLyS antibody, an anti-BR3 antibody, and a polypeptide having the sequence of SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, and SEQ ID NO. 10.
(canceled)
(canceled)
(canceled)
A method of alleviating a B-cell regulated autoimmune disorder comprising administering to a patient suffering from the disorder, a therapeutically effective amount of a CD20 binding antibody and of a BLyS antagonist, wherein the BLyS antagonist is selected from the group consisting of a BR3 immunoadhesin, an anti-BLyS antibody, an anti-BR3 antibody, and a polypeptide having the sequence of SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, and SEQ ID NO. 10.
(canceled)
A method of depleting marginal zone or germinal center B cells in a patient suffering from a B cell neoplasm or a B-cell regulated autoimmune disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of a CD20 binding antibody and of a BLyS antagonist, wherein the BLyS antagonist is selected from the group consisting of a BR3 immunoadhesin, an anti-BLyS antibody, an anti-BR3 antibody, and a polypeptide having the sequence of SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, and SEQ ID NO. 10.
53-55. (canceled)
Dependencies are inferred from the claim text.